Zealand Pharma A/S – Product Pipeline Review – H2 2011

Document Sample
Zealand Pharma A/S – Product Pipeline Review – H2 2011 Powered By Docstoc
					   Zealand Pharma A/S – Product Pipeline Review – H2
                         2011
                                                                                          Reference Code: GMDHC01423CDB

                                                                                                 Publication Date: OCT 2011




Zealand Pharma A/S – Product Pipeline Review – H2 2011                                      GMDHC01423CDB / Published OCT 2011

© Global Markets Direct. This report is a licensed product and is not to be photocopied                                 Page(1)
Zealand Pharma A/S – Product Pipeline Review




Ta b le o f Co n te n ts
Table of Contents ..................................................................................................................................................................................................... 2
      List of Tables...................................................................................................................................................................................................... 3
      List of Figures .................................................................................................................................................................................................... 4
Zealand Pharma A/S Snapshot ................................................................................................................................................................................ 5
      Zealand Pharma A/S Overview .......................................................................................................................................................................... 5
      Key Information .................................................................................................................................................................................................. 5
      Key Facts ........................................................................................................................................................................................................... 5
Zealand Pharma A/S – Research and Development Overview ................................................................................................................................. 6
      Key Therapeutic Areas ....................................................................................................................................................................................... 6
Zealand Pharma A/S – Pipeline Review ................................................................................................................................................................... 8
      Pipeline Products by Stage of Development ....................................................................................................................................................... 8
      Pipeline Products – Monotherapy ...................................................................................................................................................................... 9
Zealand Pharma A/S – Pipeline Products Glance ....................................................................................................................................................10
      Zealand Pharma A/S Clinical Stage Pipeline Products ......................................................................................................................................10
            Phase I Products/Combination Treatment Modalities ..................................................................................................................................10
Zealand Pharma A/S – Drug Profiles .......................................................................................................................................................................11
      ZP1609 .............................................................................................................................................................................................................11
            Product Description ....................................................................................................................................................................................11
            Mechanism of Action...................................................................................................................................................................................11
            R&D Progress .............................................................................................................................................................................................11
Zealand Pharma A/S – Pipeline Analysis .................................................................................................................................................................12
      Zealand Pharma A/S – Pipeline Products by Therapeutic Class ........................................................................................................................12
      Zealand Pharma A/S - Pipeline Products By Target ..........................................................................................................................................13
      Zealand Pharma A/S – Pipeline Products by Route of Administration................................................................................................................14
      Zealand Pharma A/S – Pipeline Products by Molecule Type .............................................................................................................................15
Zealand Pharma A/S – Recent Pipeline Updates....................................................................................................................................................16
Zealand Pharma A/S – Locations And Subsidiaries .................................................................................................................................................17
      Head Office .......................................................................................................................................................................................................17
Recent Developments .............................................................................................................................................................................................18
            Mar 19, 2004: Zealand Pharma Expands R&D Collaboration With Wyeth Pharmaceuticals ........................................................................18
            Oct 15, 2010: Zealand Pharma Announces Positive Phase I Trial Results For ZP1848 In Crohn's Disease ................................................18
            Oct 10, 2007: Wyeth And Zealand Pharma Advance The First Orally Available Gap Junction Modifier Into Phase I Clinical Trials..............19
            Feb 03, 2009: FDA Approves Zealand Pharma’s Investigative New Drug Application (IND) For ZP1848 To Be Administered In Humans.
            ZP1848 Is Developed For The Prevention And Treatment Of Crohn’s Disease ...........................................................................................19
            May 01, 2003: Zealand Pharma And Wyeth Enter Collaboration For Cardiovascular Therapy ....................................................................20
Financial Deals Landscape......................................................................................................................................................................................22
Zealand Pharma A/S, Pharmaceuticals & Healthcare, Deal Details .........................................................................................................................22
      Venture Financing .............................................................................................................................................................................................22
            Zealand Pharma Secures $17 Million In Second Tranche Of Series C financing .........................................................................................22
      Partnerships ......................................................................................................................................................................................................24
            PolyTherics Enters Into Research Collaboration With Zealand Pharma ......................................................................................................24
            Vyteris Enters Into Co-Development Agreement With Zealand Pharma ......................................................................................................25
            Zealand Pharma Expands Collaboration Agreement With Wyeth Pharmaceuticals .....................................................................................27
            Zealand Pharma Expands Collaboration Agreement With Wyeth Pharmaceuticals .....................................................................................28
      Licensing Agreements .......................................................................................................................................................................................29
            Zealand Pharma Enters Into Licensing And Collaboration Agreement With Boehringer Ingelheim ..............................................................29
            Zealand Pharma Extends Licensing Agreement With Sanofi-Aventis ..........................................................................................................31



Zealand Pharma A/S – Product Pipeline Review – H2 2011                                                                                                      GMDHC01423CDB / Published OCT 2011

©Global Markets Direct.. This report is a licensed product and is not to be photocopied                                                                                                                                Page(2)
Zealand Pharma A/S – Product Pipeline Review



            Zealand Pharma Enters Into Licensing Agreement With Helsinn Healthcare...............................................................................................32
      Equity Offering ..................................................................................................................................................................................................34
            Zealand Pharma Raises $4 Million Upon Exercise Of Warrants ..................................................................................................................34
            Zealand Pharma Completes Initial Public Offering For $70 Million ..............................................................................................................35
            Zealand 
				
DOCUMENT INFO
Description: Zealand Pharma A/S – Product Pipeline Review – H2 2011 Summary Global Market Direct’s pharmaceuticals report, “Zealand Pharma A/S - Product Pipeline Review - H2 2011” provides data on the Zealand Pharma A/S’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects. This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Zealand Pharma A/S’s corporate website, SEC filings, investor presentations and featured press releases, both from Zealand Pharma A/S and industry-specific third party sources, put together by Global Markets Direct’s team. Scope - Zealand Pharma A/S - Brief Zealand Pharma A/S overview including business description, key information and facts, and its locations and subsidiaries. - Review of current pipeline of Zealand Pharma A/S human therapeutic division. - Overview of pipeline therapeutics across various therapy areas. - Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe. - Product profiles for late stage and clinical stage products of Zealand Pharma A/S with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones. - Recent updates of the Zealand Pharma A/S’s pipeline in the last quarter. - Key discontinued and dormant projects. - Latest news and deals relating to the products. Reasons to buy - Evaluate Zealand Pharma A/S’s strategic position with total access to detailed information on its product pipeline. - Assess the growth potential of Zealand Pharma A/S in its therapy areas of focus. - Identify new drug targets and therapeutic classes in the Zealand Pharma A/S’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas. - Exploit in-licensin
BUY THIS DOCUMENT NOW PRICE: $500 100% MONEY BACK GUARANTEED
PARTNER GlobalMarketsDirect
Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. Global Markets Direct has a broad range of coverage over key market segments. It has a global scope, covering a broad range of countries constituting more than 90% of global revenues in each of the industries it covers. With a large dedicated research and analysis capability, Global Markets Direct employs rigorous primary and secondary research techniques in developing unique data sets and research materials. Its status as an independent research company allows Analysts to conduct trade interviews with key industry players. Access to unique databases of in-house market information further strengthens research and analysis capabilities. Materials are reviewed shaped by an expert panel of leading industry figures and representatives from key players in the relevant industries